Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellectricon Announces Project Grant Winners

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
The grant was awarded for project proposals utilizing Cellectricon’s Cellaxess ACE technology for the delivery of non-genetic material to adherent cells and cultures.

Cellectricon has announced the two winners of its Cellaxess® ACE project grant, supporting cutting-edge research in cell biology. The winners not only receive a Cellaxess ACE module and consumables, but will also benefit from Cellectricon’s on-going support and expertise throughout the project’s duration. Cellaxess ACE is a single electrode based electroporation system optimized for the in-situ transfection of all adherent cell types, which offers superior efficiency and cell viability due to minimal cell processing and the low voltages required.

The awards were granted for two categories: Applied Cell-Based Research and Basic Cell-Based Research. Dr Hakim Djaballah, Director of the HTS Core Facility, Memorial Sloan-Kettering Cancer Centre, New York, received the award for Applied Research. His project looks at small molecule delivery in 3D cell models using electroporation, benefiting from Cellectricon’s Cellaxess ACE technology to push the limits of compound delivery to all cells of a 3D spheroid, not just those at the periphery. In such a fast-paced research area, compound uptake in a 3D system has major implications for translational medicine. 

Exploring the intracellular delivery of Ca2+ channel peptides using the Cellaxess ACE, Dr Gary Stephens, Director of Pharmacology at the University of Reading School of Pharmacy, received the award for Basic Cell-based Research. The group has recently developed synthetic peptides for decreasing the Ca2+ influx into neurons, which therefore modulates synaptic transmission. Using the Cellaxess ACE to deliver these peptides will be instrumental in examining their modulatory effects in adherent neurons, potentially leading to therapeutic agents in areas such as pharmacoresistant pain. 

Dr Johan Pihl, Product Manager for the Cellaxess ACE, comments: “We were delighted with the response to our Cellaxess Project Grant – with so many highly qualified applications, choosing the winning abstracts was a tough decision. It’s going to be exciting to see how our Cellaxess technology enhances this cutting-edge research.” 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services
The company, a leading provider of advanced cell-based discovery services, has appointed Dr Edwin Johnson, Director of The Stockholm Brain Institute, as the first member of its new Scientific Advisory Board.
Thursday, July 09, 2015
UCL’s Novel Approach to Research in Biologically-Relevant Models
Cellectricon and UCL unite to present a webinar, March 27, 11am-12pm EDT.
Wednesday, March 19, 2014
Presenting Phenotypic Screening Strategies for Chronic Pain Research
Cellectricon explores novel phenotypic assay designs in a webinar, 5 September, 11am-12pm (EDT).
Wednesday, August 21, 2013
Cellectricon Launches Grant to Fund Electroporation-based Research
New Cellaxess® Project Grant supports advanced research projects.
Wednesday, July 10, 2013
Identifying Unknown Modulators of Pain with New Phenotypic Assays
Cellectricon presentation: SMi Pain Therapeutics conference, 20 May, 11am.
Tuesday, May 14, 2013
Dr. Paul Karila appointed Head of Discovery Services at Cellectricon AB
Discovery services will be based on automated cellular electric field manipulation for novel screening applications.
Wednesday, June 13, 2012
Cellectricon Receives Milestone Order for Cellaxess®HT High Throughput RNAi Screening System
Cellectricon receives the largest single order to deliver three Cellaxess®HT systems to a leading US biotech firm.
Friday, November 14, 2008
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Battery Component Found to Harm Key Soil Microorganism
The material at the heart of the lithium ion batteries that power electric vehicles, laptop computers and smartphones has been shown to impair a key soil bacterium, according to new research.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!